Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Evaluating the suitability of checkpoint inhibitors with biomarkers in patients with melanoma

Matteo Carlino, FRACP, PhD, University of Sydney and Westmead Hospital, Sydney, Australia, comments on the current use of biomarkers to assess clinical response in patients with melanoma receiving checkpoint inhibitors. Whilst various lab-based biomarkers exist such as the presence of BRAF mutations can predict response to combination therapies, histological subtypes of melanoma are more applicable in a clinical setting, where certain forms of melanoma such as desmoplastic melanoma are more receptive to monotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.